Table 3.
Outcome measures at different time periods
| Domain | Outcome measure | Stage of HIE | T1 Discharge | T2 4 months | T2 6 months | T3 12 months | T4 18 months | T5 24 months |
|---|---|---|---|---|---|---|---|---|
| Survival | Survival or death | X | X | X | X | X | X | X |
| Neurologic exam at discharge | Neurologically normal or abnormal | X | X | |||||
| Cranial Ultrasonography | Cranial USS abnormality | X | X | |||||
| Neurologic examination at clinic visits | Malawi Developmental Assessment Tool (MDAT) scores | X | X | X | X | X | ||
| Laboratory levels of EPO, NRBC, and NRBC/100 WBC | Levels of NRBC and NRBC/100WBC in relation to outcome | X | X | |||||
| Adverse reactions to EPO | Safety of the medications based on the presence or absence of any adverse event | X | X | X | X | X | X | |
| Gross Motor Function Classification System (GMFCS) assessment system | Those with cerebral palsy are further categorized based on features present on standardized neurologic examination using GMFCS | X | X | X | X | X |
T1− T5 - The five time periods for assessment; NRBC Nucleated red blood cells, GMFCS Gross motor function classification system.